Top

Endocrine

Published in:

01-02-2020 | Metformin | Meta-Analysis

Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials

Authors: Shuwei Weng, Yonghong Luo, Ziyu Zhang, Xin Su, Daoquan Peng

Published in: Endocrine | Issue 2/2020

Abstract

Purpose

To evaluate the effects of metformin on serum lipid profiles in nondiabetic adults through a comprehensive meta-analysis.

Methods

In the present meta-analysis, randomized and controlled trials were collected by searching PubMed, Embase, and Cochrane Libraries from inception to April 2019. Compared with placebos, the effects of metformin treatment on lipid profiles in nondiabetic adults were evaluated.

Results

Forty-seven studies from 45 articles including 5731 participants were enrolled. Pooled results showed that metformin had significant effects on total cholesterol (mean change −6.57 mg/dl; 95% CI −9.66, −3.47; P = 0.000) and LDL-c (mean change −4.69 mg/dl; 95% CI −7.38, −2.00; P = 0.001), but insignificant effects on HDL-c (mean change −4.33 mg/dl; 95% CI −9.62, 0.96; P = 0.109) and triglyceride (mean change −0.85 mg/dl; 95% CI −0.36, 2.06; P = 0.169). Significant heterogeneities were found for all lipid profiles (HDL-c = 85.5%; LDL-c = 59.9%; total cholesterol = 75.3% and triglyceride = 67.1%). Different from the pooled data, in a subgroup analysis, the effect of metformin on triglyceride in patients with polycystic ovarian syndrome (PCOS) was significant with a mean reduction of 8.15 mg/dl. In addition, sensitivity analysis showed that the pooled effects of metformin on serum lipid profiles were stable. Publication bias derived from funnel plots or Begg’s tests (P = 0.933, 0.860, 0.904, and 0.567 for HDL-c, LDL-c, total cholesterol, and triglyceride, respectively) was not significant.

Conclusion

This meta-analysis revealed that metformin could reduce total cholesterol and LDL-c in nondiabetic adults. In addition, metformin might exert a triglyceride-lowering effect in nondiabetics with PCOS status.

Available only for authorised users

C. Bommer, E. Heesemann, V. Sagalova, J. Manne-Goehler, R. Atun, T. Barnighausen, S. Vollmer, The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 5(6), 423–430 (2017). https://doi.org/10.1016/s2213-8587(17)30097-9 CrossRefPubMed

S. Roberts, E. Barry, D. Craig, M. Airoldi, G. Bevan, T. Greenhalgh, Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open 7(11), e017184 (2017). https://doi.org/10.1136/bmjopen-2017-017184 CrossRefPubMedPubMedCentral

I. Hopper, B. Billah, M. Skiba, H. Krum, Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur. J. Cardiovasc. Prev. Rehabil. 18(6), 813–823 (2011). https://doi.org/10.1177/1741826711421687 CrossRefPubMed

M.K. Ali, K.M. Bullard, S. Saydah, G. Imperatore, E.W. Gregg, Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 6(5), 392–403 (2018). https://doi.org/10.1016/s2213-8587(18)30027-5 CrossRefPubMedPubMedCentral

C. Merlotti, A. Morabito, A.E. Pontiroli, Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes. Metab. 16(8), 719–727 (2014). https://doi.org/10.1111/dom.12270 CrossRefPubMed

UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131), 854–865 (1998). https://doi.org/10.1016/s0140-6736(98)07037-8 CrossRef

T.J. Orchard, M. Temprosa, E. Barrett-Connor, S.E. Fowler, R.B. Goldberg, K.J. Mather, S.M. Marcovina, M. Montez, R.E. Ratner, C.D. Saudek, H. Sherif, K.E. Watson, Long-term effects of the diabetes prevention program interventions on cardiovascular risk factors: a report from the DPP outcomes study. Diabet. Med. 30(1), 46–55 (2013). https://doi.org/10.1111/j.1464-5491.2012.03750.x CrossRefPubMedPubMedCentral

S.R. Salpeter, N.S. Buckley, J.A. Kahn, E.E. Salpeter, Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 121(2), 149–157.e142 (2008). https://doi.org/10.1016/j.amjmed.2007.09.016 CrossRefPubMed

L. Zhou, H. Liu, X. Wen, Y. Peng, Y. Tian, L. Zhao, Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. J. Hypertens. 35(1), 18–26 (2017). https://doi.org/10.1097/HJH.0000000000001119 CrossRefPubMed

10.

A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 62(10), e1–e34 (2009). https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefPubMed

11.

S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 5, 13 (2005). https://doi.org/10.1186/1471-2288-5-13 CrossRefPubMedPubMedCentral

12.

A. Fontbonne, M.A. Charles, I. Juhan-Vague, J.M. Bard, P. André, F. Isnard, J.M. Cohen, P. Grandmottet, P. Vague, M.E. Safar et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 19(9), 920–926 (1996). https://doi.org/10.2337/diacare.19.9.920 CrossRefPubMed

13.

C.L. Li, C.Y. Pan, J.M. Lu, Y. Zhu, J.H. Wang, X.X. Deng, F.C. Xia, H.Z. Wang, H.Y. Wang, Effect of metformin on patients with impaired glucose tolerance. Diabet. Med. 16(6), 477–481 (1999). https://doi.org/10.1046/j.1464-5491.1999.00090.x CrossRefPubMed

14.

P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, M. Caputo, E. Zanolin, M. Muggeo, Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85(1), 139–146 (2000). https://doi.org/10.1210/jcem.85.1.6293 CrossRefPubMed

15.

M.A. Charles, E. Eschwège, P. Grandmottet, F. Isnard, J.M. Cohen, J.L. Bensoussan, H. Berche, O. Chapiro, P. André, P. Vague, et al., Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab. Res. Rev. 16(1), 2–7 (2000). https://doi.org/10.1002/(sici)1520-7560(200001/02)16:13.0.co;2-g CrossRefPubMed

16.

M. Lehtovirta, B. Forsén, M. Gullström, M. Häggblom, J.G. Eriksson, M.R. Taskinen, L. Groop, Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet. Med. 18(7), 578–583 (2001). https://doi.org/10.1046/j.1464-5491.2001.00539.x CrossRefPubMed

17.

C.J. Kelly, D. Gordon, The effect of metformin on hirsutism in polycystic ovary syndrome. Eur. J. Endocrinol. 147(2), 217–221 (2002). https://doi.org/10.1530/eje.0.1470217 CrossRefPubMed

18.

K.H. Chou, H. von Eye Corleta, E. Capp, P.M. Spritzer, Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm. Metab. Res. 35(2), 86–91 (2003). https://doi.org/10.1055/s-2003-39056 CrossRefPubMed

19.

G.A. Maciel, J.M. Soares Junior, E.L. Alves da Motta, M. Abi Haidar, G.R. de Lima, E.C. Baracat, Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil. Steril. 81(2), 355–360 (2004). https://doi.org/10.1016/j.fertnstert.2003.08.012 CrossRefPubMed

20.

A. Gambineri, C. Pelusi, S. Genghini, A.M. Morselli-Labate, M. Cacciari, U. Pagotto, R. Pasquali, Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. 60(2), 241–249 (2004). https://doi.org/10.1111/j.1365-2265.2004.01973.x CrossRef

21.

A.E. Caballero, A. Delgado, C.A. Aguilar-Salinas, A.N. Herrera, J.L. Castillo, T. Cabrera, F.J. Gomez-Perez, J.A. Rull, The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 89(8), 3943–3948 (2004). https://doi.org/10.1210/jc.2004-0019 CrossRefPubMed

22.

D.A. Stakos, D.P. Schuster, E.A. Sparks, C.F. Wooley, K. Osei, H. Boudoulas, Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart (Br. Card. Soc.) 91(5), 589–594 (2005). https://doi.org/10.1136/hrt.2003.027722 CrossRef

23.

T. Tang, J. Glanville, C.J. Hayden, D. White, J.H. Barth, A.H. Balen, Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. (Oxf., Engl.) 21(1), 80–89 (2006). https://doi.org/10.1093/humrep/dei311 CrossRef

24.

J. Lord, R. Thomas, B. Fox, U. Acharya, T. Wilkin, The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome—a randomised, double-blind, placebo-controlled trial. BJOG 113(7), 817–824 (2006). https://doi.org/10.1111/j.1471-0528.2006.00966.x CrossRefPubMed

25.

C. Guimaraes, L.R. Pereira, N. Iucif Junior, E.J. Cesarino, C.A. de Almeida, D. de Carvalho, R.H. Queiroz, Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arq. Bras. Endocrinol. Metab. 50(6), 1020–1025 (2006). https://doi.org/10.1590/s0004-27302006000600007 CrossRef

26.

A. Gambineri, L. Patton, A. Vaccina, M. Cacciari, A.M. Morselli-Labate, C. Cavazza, U. Pagotto, R. Pasquali, Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J. Clin. Endocrinol. Metab. 91(10), 3970–3980 (2006). https://doi.org/10.1210/jc.2005-2250 CrossRefPubMed

27.

T. Baptista, J. Martínez, A. Lacruz, N. Rangel, S. Beaulieu, A. Serrano, Y. Arapé, M. Martinez, S. De Mendoza, L. Teneud, L. Hernández, Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can. J. Psychiatry 51(3), 192–196 (2006). https://doi.org/10.1177/070674370605100310 CrossRefPubMed

28.

B. Trolle, A. Flyvbjerg, U. Kesmodel, F.F. Lauszus, Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum. Reprod. 22(11), 2967–2973 (2007). https://doi.org/10.1093/humrep/dem271 CrossRefPubMed

29.

S. Palomba, A. Falbo, T. Russo, F. Manguso, A. Tolino, F. Zullo, P. De Feo, F. Orio, Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(8), 3128–3135 (2007). https://doi.org/10.1210/jc.2007-0441 CrossRefPubMed

30.

L.G. Kraemer de Aguiar, C.M. Laflor, L. Bahia, N.R. Villela, N. Wiernsperger, D.A. Bottino, E. Bouskela, Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome. Diabet. Med. 24(3), 272–279 (2007). https://doi.org/10.1111/j.1464-5491.2007.02082.x CrossRefPubMed

31.

M.A. Karimzadeh, M. Eftekhar, R. Taheripanah, N. Tayebi, L. Sakhavat, F. Zare, The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertil. Soc. J. 12(3), 174–178 (2007)

32.

T. Baptista, N. Rangel, V. Fernández, E. Carrizo, Y. El Fakih, E. Uzcátegui, T. Galeazzi, M.A. Gutiérrez, M. Servigna, A. Dávila, et al., Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophrenia Res. 93(1–3), 99–108 (2007). https://doi.org/10.1016/j.schres.2007.03.029 CrossRef

33.

A. Fontbonne, I. Diouf, M. Baccara-Dinet, E. Eschwege, M.A. Charles, Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab. 35(5), 385–391 (2009). https://doi.org/10.1016/j.diabet.2009.03.005 CrossRefPubMed

34.

D. Romualdi, M. Giuliani, F. Cristello, A.M. Fulghesu, L. Selvaggi, A. Lanzone, M. Guido, Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil. Steril. 93(7), 2303–2310 (2010). https://doi.org/10.1016/j.fertnstert.2009.01.114 CrossRefPubMed

35.

C.F. Otta, M. Wior, G.S. Iraci, R. Kaplan, D. Torres, M.I. Gaido, E.P. Wyse, Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol. Endocrinol. 26(3), 173–178 (2010). https://doi.org/10.3109/09513590903215581 CrossRef

36.

S.S. Lim, R.J. Norman, P.M. Clifton, M. Noakes, The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr. Metab. Cardiovasc Dis. 21(4), 261–268 (2011). https://doi.org/10.1016/j.numecd.2009.10.006 CrossRefPubMed

37.

G. Ladson, W.C. Dodson, S.D. Sweet, A.E. Archibong, A.R. Kunselman, L.M. Demers, N.I. Williams, P. Coney, R.S. Legro, The effects of metformin with lifestyle therapy in polycystic ovary syndrome: A randomized double-blind study. Fertil. Steril. 95(3), 1059–1066.e1057 (2011). https://doi.org/10.1016/j.fertnstert.2010.12.002 CrossRefPubMed

38.

W. Wei, H. Zhao, A. Wang, M. Sui, K. Liang, H. Deng, Y. Ma, Y. Zhang, H. Zhang, Y. Guan, A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur. J. Endocrinol. 166(1), 99–105 (2012). https://doi.org/10.1530/EJE-11-0616 CrossRefPubMed

39.

R. Krysiak, B. Okopien, The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. Metab.: Clin. Exp. 62(1), 39–43 (2013). https://doi.org/10.1016/j.metabol.2012.06.009 CrossRef

40.

S.K. Malin, J. Nightingale, S.E. Choi, S.R. Chipkin, B. Braun, Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults. Obes. (Silver spring, md.) 21(1), 93–100 (2013). https://doi.org/10.1002/oby.20235 CrossRef

41.

L.F. Jarskog, R.M. Hamer, D.J. Catellier, D.D. Stewart, L. Lavange, N. Ray, L.H. Golden, J.A. Lieberman, T.S. Stroup, Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am. J. Psychiatry 170(9), 1032–1040 (2013). https://doi.org/10.1176/appi.ajp.2013.12010127 CrossRefPubMed

42.

C.H. Chen, M.C. Huang, C.F. Kao, S.K. Lin, P.H. Kuo, C.C. Chiu, M.L. Lu, Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 74(5), e424–e430 (2013). https://doi.org/10.4088/JCP.12m08186 CrossRefPubMed

43.

Y. An, Z. Sun, Y. Zhang, B. Liu, Y. Guan, M. Lu, The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin. Endocrinol. 80(3), 425–431 (2013). https://doi.org/10.1111/cen.12294 CrossRef

44.

R. Worsley, F. Jane, P.J. Robinson, R.J. Bell, S.R. Davis, Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric 18(2), 270–277 (2015). https://doi.org/10.3109/13697137.2014.954997 CrossRefPubMed

45.

D. Preiss, S.M. Lloyd, I. Ford, J.J. McMurray, R.R. Holman, P. Welsh, M. Fisher, C.J. Packard, N. Sattar, Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. The lancet. Diabetes Endocrinol. 2(2), 116–124 (2014). https://doi.org/10.1016/S2213-8587(13)70152-9 CrossRef

46.

H.R. Mogul, R. Freeman, K. Nguyen, M. Frey, L.A. Klein, S. Jozak, K. Tanenbaum, Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain. PLoS ONE 9(9), e108264 (2014). https://doi.org/10.1371/journal.pone.0108264 CrossRefPubMedPubMedCentral

47.

M. Amiri, M. Golsorkhtabaramiri, S. Esmaeilzadeh, F. Ghofrani, A. Bijani, L. Ghorbani, M.A. Delavar, Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet. J. Reprod. Infertil. 15(4), 205–213 (2014)PubMedPubMedCentral

48.

W. Xu, Y.Y. Deng, L. Yang, S. Zhao, J. Liu, Z. Zhao, L. Wang, P. Maharjan, S. Gao, Y. Tian, X. Zhuo, Y. Zhao, J. Zhou, Z. Yuan, Y. Wu, Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. Transl. Res. 166(5), 451–458 (2015). https://doi.org/10.1016/j.trsl.2015.06.002 CrossRefPubMed

49.

C.P.H. Lexis, A.N.A van der Horst-Schrivers, E. Lipsic, M.A.E. Valente, A.C.M. Kobold, R.A. de Boer, D.J. van Veldhuisen, P. van der Harst, I.C.C. van der Horst et al. The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. BMJ Open Diabetes Res Care 3(1), (2015). https://doi.org/10.1136/bmjdrc-2015-000090 CrossRef

50.

P. Hebrani, A.A. Manteghi, F. Behdani, E. Hessami, K.A. Rezayat, M.N. Marvast, A.A. Rezayat, Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J. Res. Med. Sci. 20(4), 364–371 (2015)PubMedPubMedCentral

51.

G. Ghazeeri, H.A. Abbas, B. Skaff, S. Harajly, J. Awwad, Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. J. Endocrinol. Investig. 38(6), 643–651 (2015). https://doi.org/10.1007/s40618-015-0237-3 CrossRef

52.

R.R. Wu, F.Y. Zhang, K.M. Gao, J.J. Ou, P. Shao, H. Jin, W.B. Guo, P.K. Chan, J.P. Zhao, Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Mol. Psychiatry 21(11), 1537–1544 (2016). https://doi.org/10.1038/mp.2015.221 CrossRefPubMedPubMedCentral

53.

S. Singh, A. Bhansali, Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 16(1), 12 (2016). https://doi.org/10.1186/s12895-016-0049-y CrossRefPubMedPubMedCentral

54.

S.J. Griffin, M. Angelyn Bethel, R.R. Holman, K. Khunti, N. Wareham, G. Brierley, M. Davies, A. Dymond, R. Eichenberger, P. Evans et al. Metformin in non-diabetic hyperglycaemia: the glint feasibility RCT. Health technology assessment 22(18) (2018). https://doi.org/10.3310/hta22180 CrossRef

55.

M. Dornelles Severo, T. Stürmer Andrade, V. Correa Junior, A. Antonio Naujorks, M. Gus, B.D. Schaan, Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial. Endocrine 59(1), 66–71 (2018). https://doi.org/10.1007/s12020-017-1462-7 CrossRefPubMed

56.

M. Zang, A. Zuccollo, X. Hou, D. Nagata, K. Walsh, H. Herscovitz, P. Brecher, N.B. Ruderman, R.A. Cohen, AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279(46), 47898–47905 (2004). https://doi.org/10.1074/jbc.M408149200 CrossRefPubMed

57.

Y. Li, S. Xu, M.M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J.Y. Shyy, B. Gao, M. Wierzbicki, T.J. Verbeuren, R.J. Shaw, R.A. Cohen, M. Zang, AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13(4), 376–388 (2011). https://doi.org/10.1016/j.cmet.2011.03.009 CrossRefPubMedPubMedCentral

58.

G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, D.E. Moller, Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 108(8), 1167–1174 (2001). https://doi.org/10.1172/jci13505 CrossRefPubMed

59.

S.K. Malin, S.R. Kashyap, Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 323–329 (2014). https://doi.org/10.1097/med.0000000000000095 CrossRefPubMed

60.

M.H. Hallak, M.Z. Nomani, Body weight loss and changes in blood lipid levels in normal men on hypocaloric diets during Ramadan fasting. Am. J. Clin. Nutr. 48(5), 1197–1210 (1988). https://doi.org/10.1093/ajcn/48.5.1197 CrossRefPubMed

61.

A. Wang, T. Mo, Q. Li, C. Shen, M. Liu, The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. Endocrine 64(2), 220–232 (2019). https://doi.org/10.1007/s12020-019-01860-w CrossRefPubMed

62.

D.F. Vine, Y. Wang, M.M. Jetha, G.D. Ball, S.D. Proctor, Impaired ApoB-lipoprotein and triglyceride metabolism in obese adolescents with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 102(3), 970–982 (2017). https://doi.org/10.1210/jc.2016-2854 CrossRefPubMed

63.

R. Patel, G. Shah, Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 33(9), 1545–1557 (2017). https://doi.org/10.1080/03007995.2017.1279597 CrossRefPubMed

64.

Diabetes Prevention Program Research Group, Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3(11), 866–875 (2015). https://doi.org/10.1016/s2213-8587(15)00291-0

65.

W.H. Herman, The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35(4), 723–730 (2012). https://doi.org/10.2337/dc11-1468

66.

B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E.H. Barnes, M. Voysey, A. Gray, R. Collins, C. Baigent, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012). https://doi.org/10.1016/s0140-6736(12)60367-5 CrossRefPubMed

67.

M. Solymar, I. Ivic, L. Poto, P. Hegyi, A. Garami, P. Hartmann, E. Petervari, L. Czopf, A. Hussain, Z. Gyongyi, P. Sarlos, M. Simon, P. Matrai, B. Berczi, M. Balasko, Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly—a meta-analysis. PLoS ONE 13(11), e0207947 (2018). https://doi.org/10.1371/journal.pone.0207947 CrossRefPubMedPubMedCentral

68.

J.A. Kiayias, E.D. Vlachou, E.L. Papadodima, Metformin and lipoprotein(a) levels. Diabetes Care 22(5), 859 (1999). https://doi.org/10.2337/diacare.22.5.859b CrossRefPubMed

Title: Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials
Authors: Shuwei Weng
Yonghong Luo
Ziyu Zhang
Xin Su
Daoquan Peng
Publication date: 01-02-2020
Publisher: Springer US
Keyword: Metformin
Published in: Endocrine / Issue 2/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02190-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Sonographic features of follicular variant of papillary thyroid carcinoma (FV-PTC) and diagnostic performance of the 2017 ACR TI-RADS in FV-PTC

Orbital metastases from neuroendocrine neoplasms: clinical implications and outcomes

Rapid changes in neuroendocrine regulation may contribute to reversal of type 2 diabetes after gastric bypass surgery

A prolapsing pituitary adenoma

Metabolic profiling of acromegaly using a GC–MS-based nontargeted metabolomic approach

Teriparatide (rhPTH 1–34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage